Prognostic and predictive implications of EGFR mutations, EGFR copy number and KRAS mutations in advanced stage lung adenocarcinoma
L Bonanno, M Schiavon, G Nardo… - Anticancer …, 2010 - ar.iiarjournals.org
Background/Aim: Gefitinib and erlotinib were shown to be particularly effective in a clinically
selected subpopulation of non-small cell lung cancer patients (NSCLC): adenocarcinoma …
selected subpopulation of non-small cell lung cancer patients (NSCLC): adenocarcinoma …
Association of KRAS and EGFR mutations with survival in patients with advanced lung adenocarcinomas
BACKGROUND: Lung adenocarcinomas can be distinguished by identifying mutated driver
oncogenes, including epidermal growth factor receptor (EGFR) and KRAS. Mutations in …
oncogenes, including epidermal growth factor receptor (EGFR) and KRAS. Mutations in …
[HTML][HTML] Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma
JS Tseng, TY Yang, CR Tsai, KC Chen, KH Hsu… - Journal of thoracic …, 2015 - Elsevier
Background Epidermal growth factor receptor (EGFR) mutation status in lung cancer can
effectively predict EGFR-tyrosine kinase inhibitor (TKI) efficacy. We evaluated the role of …
effectively predict EGFR-tyrosine kinase inhibitor (TKI) efficacy. We evaluated the role of …
EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas?
Background EGFR tyrosine kinase inhibitors (TKIs) have greatly improved the outcomes of
EGFR mutation-positive adenocarcinomas of the lung. In contrast, the significance of EGFR …
EGFR mutation-positive adenocarcinomas of the lung. In contrast, the significance of EGFR …
Concurrence of EGFR amplification and sensitizing mutations indicate a better survival benefit from EGFR-TKI therapy in lung adenocarcinoma patients
L Shan, Z Wang, L Guo, H Sun, T Qiu, Y Ling, W Li, L Li… - Lung Cancer, 2015 - Elsevier
Objectives Tumor heterogeneity, which causes different EGFR mutation abundance, is
believed to be responsible for varied progression-free survival (PFS) in lung …
believed to be responsible for varied progression-free survival (PFS) in lung …
[HTML][HTML] Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma
Z Lohinai, MA Hoda, K Fabian, G Ostoros… - Journal of thoracic …, 2015 - Elsevier
Introduction Although classic sensitizing mutations of epidermal growth factor receptor
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …
(EGFR) are positive predictive markers for EGFR tyrosine kinase inhibitors (TKIs) in lung …
Common and rare EGFR and KRAS mutations in a Dutch non-small-cell lung cancer population and their clinical outcome
GSMA Kerner, E Schuuring, J Sietsma… - PloS one, 2013 - journals.plos.org
Introduction In randomly assigned studies with EGFR TKI only a minor proportion of patients
with NSCLC have genetically profiled biopsies. Guidelines provide evidence to perform …
with NSCLC have genetically profiled biopsies. Guidelines provide evidence to perform …
Efficacy and long-term survival of advanced lung adenocarcinoma patients with uncommon EGFR mutations treated with 1st generation EGFR-TKIs compared with …
H Li, C Wang, Z Wang, Y Hu, G Zhang, M Zhang… - Lung Cancer, 2019 - Elsevier
Purpose This study aims to understand the effects and long-term survival of 1st generation
epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) or platinum-based …
epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKI) or platinum-based …
[HTML][HTML] EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase …
Y Liu, H Wang, S Yang, Y Yang, Y Wu… - Journal of Thoracic …, 2022 - ncbi.nlm.nih.gov
Background Epidermal growth factor receptor tyrosine kinases inhibitors (EGFR-TKIs) are
currently recognized as the standard treatment for advanced non-small cell lung cancer …
currently recognized as the standard treatment for advanced non-small cell lung cancer …
[HTML][HTML] Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non–small-cell lung …
Background Epidermal growth factor and v-Ki-ras2 Kirsten ras sarcoma (KRAS) mutation
status, although associated with EGFR-tyrosine kinase inhibitor (TKI) efficacy, has not been …
status, although associated with EGFR-tyrosine kinase inhibitor (TKI) efficacy, has not been …
相关搜索
- lung cancer kras mutations
- copy number prognostic and predictive implications
- copy number implications of egfr mutations
- lung adenocarcinoma patients
- sensitizing mutations egfr tki
- lung adenocarcinomas mutational status
- lung adenocarcinoma molecular diagnosis
- lung adenocarcinoma mutational analysis
- lung adenocarcinoma clinical consequence
- primary lung adenocarcinomas
- lung adenocarcinomas clinicopathological predictors
- lung adenocarcinoma cytological specimens
- egfr mutation cell carcinoma
- rare egfr mutations
- egfr mutations long term
- survival benefit egfr tki